Ayala Pharmaceuticals, Inc.

Equities

ADXS

US0076244062

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:57:26 2024-05-15 pm EDT			5-day change	1st Jan Change
0.19 ^USD	+33.33%		-69.60%	-71.51%

Apr. 16	Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 16	Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Advaxis, Inc. Announces Executive Changes

July 06, 2017 at 04:30 pm EDT

Daniel J. O'Connor, chief executive officer, president and board member of Advaxis, Inc. announced his resignation from the company and its board of directors on July 6, 2017. Anthony (Tony) Lombardo will immediately assume the role of interim CEO to continue leading Advaxis in its advancement of multiple cancer immunotherapies based on its proprietary Lm Technology™. Lombardo, who joined the company as chief business officer earlier 2017, is an accomplished industry veteran with nearly 30 years of leadership experience in the life sciences industry, including previous positions as president and CEO of E-Z-EM Inc. and president of ALI Imaging Systems, Inc. He will serve as interim CEO until a permanent leader is selected.

Latest news about Ayala Pharmaceuticals, Inc.

Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 16	CI
Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 15	CI
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	Apr. 11	DJ
North American Morning Briefing : Focus Turns to -2-	Apr. 04	DJ
Ayala Pharmaceuticals, Inc. Announces Departure of Roy Golan as Chief Financial Officer, Effective from June 25, 2024	Apr. 03	CI
Andres Guttierez, Chief Medical Officer and Executive Vice President, Departs from Ayala Pharmaceuticals, Inc	Apr. 03	CI
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
Immunome, Inc. completed the acquisition of Assets from Ayala Pharmaceuticals, Inc..	Mar. 24	CI
North American Morning Briefing : Fed's Preferred -2-	Feb. 29	DJ
North American Morning Briefing : Nvidia Ignites -2-	Feb. 22	DJ
Ayala Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 3 Ringside Study Evaluating AL102 in Desmoid Tumors	Feb. 20	CI
Sector Update: Health Care Stocks Gain Late Afternoon	Feb. 06	MT
Top Midday Gainers	Feb. 06	MT
Immunome to Acquire Potential Desmoid Tumor Treatment From Ayala Pharmaceuticals; Shares Climb	Feb. 06	MT
Immunome, Inc. entered into a definitive asset purchase agreement to acquire Assets from Ayala Pharmaceuticals, Inc. for $94.2 million.	Feb. 05	CI
North American Morning Briefing : Stock Futures -2-	Nov. 27	DJ
Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
North American Morning Briefing : Stocks Futures Steady on Rates Optimism	Nov. 20	DJ
Ayala Pharmaceuticals, Inc. announced that it has received $4 million in funding from Israel Biotech Fund, Arkin Bio Venture Partners Ltd., BioTelemetry, Inc.	Nov. 16	CI
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023	23-10-23	CI
Ayala Pharmaceuticals, Inc. Announces Executive Changes	23-10-20	CI
BioSight Ltd. acquired Ayala Pharmaceuticals, Inc. in a reverse merger transaction.	23-10-17	CI
North American Morning Briefing : Stock Futures Point Lower Ahead of Big Bank Earnings	23-10-13	DJ
North American Morning Briefing : Investors Await -2-	23-10-06	DJ
North American Morning Briefing : Mood Improves as -2-	23-09-29	DJ

Chart Ayala Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). Aspacytarabine (BST-236) is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine. It is also focused on the development and commercialization of proprietary Listeria monocytogenes (Lm)-based antigen delivery products. These efforts are primarily focused on the development of ADXS-504, a Lm-based therapy for early-stage prostate cancer.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.19

Average target price

Consensus

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AYALA PHARMACEUTICALS, INC.	-71.51%	8.1M
MODERNA, INC.	+29.77%	49.46B
IQVIA HOLDINGS INC.	+1.00%	42.58B
LONZA GROUP AG	+49.79%	42.49B
CELLTRION, INC.	-5.26%	29.09B
ICON PUBLIC LIMITED COMPANY	+13.68%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-22.99%	18.64B
BIO-TECHNE CORPORATION	+8.22%	13.16B
MEDPACE HOLDINGS, INC.	+32.41%	12.55B
UNITED THERAPEUTICS CORPORATION	+24.01%	12.1B

Other Biotechnology & Medical Research